XML 68 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Segment and Geographic Information

12 Months Ended

Dec. 31, 2019

Segment Reporting [Abstract]

Segment and Geographic Information

14. Segment and Geographic Information

The Company has determined that the chief executive officer is the chief operating decision maker (“CODM”). The CODM reviews financial information presented for the Company’s various clinical trial programs as well as results on a consolidated basis. License revenues and development revenues received are not allocated to various programs for purposes of determining a profit measure and resource allocation decisions are made by the CODM based primarily on consolidated results. As such, the Company has concluded that it operates as one segment. Supplemental enterprise-wide information has been presented below.

Geographic Revenues

Geographic revenues, which are based on the bill-to region, are as follows (in thousands):

		Years Ended December 31,
		2019				2018				2017
Europe		$	132,400			$	112,916			$	110,861
Japan (related party)			122,475				100,002				20,111
All other			1,702				40				24
Total revenue		$	256,577			$	212,958			$	130,996

Revenues to other regions include the Company commercial sales of roxadustat drug product in China starting in the third quarter of 2019. See Note 3 for details.

Geographic Long-Lived Assets

Property and equipment, net by geographic location are as follows (in thousands):

		December 31,
		2019				2018
United States		$	27,325			$	103,539
China			15,418				23,659
Total property and equipment		$	42,743			$	127,198

Finance lease right-of-use assets and operating lease right-of-use assets, net by geographic location are as follows (in thousands):

		December 31,
		2019				2018
United States		$	39,237			$	—
China			365				—
Total finance lease right-of-use assets		$	39,602			$	—
United States		$	75			$	—
China			1,856				—
Total operating lease right-of-use assets		$	1,931			$	—

Customer Concentration

Substantially all of the Company’s revenues to date have been generated from the following collaboration partners that respectively accounted for 10% or more of the Company’s total revenue and accounts receivable:

		Percentage of Revenue												Percentage of Accounts Receivable
		Years Ended December 31,												December 31,
		2019				2018				2017				2019				2018
Astellas—Related party			48	%			47	%			15	%			17	%			74	%
AstraZeneca			52	%			53	%			85	%			81	%			26	%

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Name:	us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration